Regenesis Biomedical, Inc.

Regenesis Biomedical, Inc. develops innovative non-drug solutions for pain relief, focusing on the self-administration of therapeutic treatments to enhance patient quality of life and alleviate reliance on pharmaceuticals. Founded in 1996 in Scottsdale, US, Regenesis Biomedical, Inc. specializes in non-drug pain relief solutions.

The company has undergone strategic pivots to enhance its product offerings and has raised a total of USD 5. 30 mn through 5 different funding rounds, with the most recent being a Series C financing in June 2011. CEO Tom Eisiminger leads the company, which serves clients primarily in the United States, including a significant number of veterans. Regenesis specializes in non-drug pain relief solutions, primarily through its core product, Reprieve, which utilizes electromagnetic shortwave diathermy therapy.

This innovative treatment allows patients to self-administer therapeutic relief from pain in the comfort of their homes, addressing the need for effective, non-pharmaceutical pain management solutions. The primary user base consists of individuals suffering from chronic pain, including over 24,000 veterans who have utilized the therapy, marketed directly to consumers and healthcare professionals in the United States. Regenesis generates revenue through direct-to-consumer sales of its flagship product, Reprieve, alongside potential partnerships with healthcare providers. The transaction structure facilitates direct sales to patients, allowing them to purchase the device and access necessary support services.

While specific pricing details are not disclosed, the company emphasizes the accessibility of its offerings to individuals seeking non-drug alternatives for pain relief. In June 2011, Regenesis Biomedical, Inc. raised USD 5. 3 mn in Series C financing from co-lead investors Fulcrum Equity Partners and TGap Ventures, along with Solstice Capital.

The company plans to utilize this funding to enhance its product line and expand into new markets, although specific upcoming product launches and target regions have not been detailed.